About Supriya Lifescience Limited

Supriya Lifescience Limited is a Mumbai-headquartered active pharmaceutical ingredients (API) manufacturer established as a partnership in 1987 and incorporated as a public limited company in 2008, serving over 1,500 customers across more than 120 countries with 38 APIs spanning anti‑histamines, anaesthetics, vitamins, analgesics, and anti‑asthmatics. Its primary manufacturing facility at Lote Parshuram, Maharashtra spans 33,000 sq. mts with 5 therapy-based blocks and total reactor capacity of 932 KLPD after commissioning Module E, carrying global accreditations including USFDA, EDQM, AIFA (Italy), TGA (Australia), KFDA (Korea), PMDA (Japan), NMPA (China), COFEPRIS (Mexico), ANVISA (Brazil), WHO‑GMP, ISO 9001:2015, FAMI‑QS, and Halal, alongside a second R&D/formulations hub at Ambernath focused on value-added products and CDMO/CMO opportunities. The company reported export-led operations with 85% of FY 2024–25 revenue from international markets, key customers including Haleon, Kenvue, Sanofi, GSK, Teva, Cipla, Syntec do Brasil, and leading Indian formulators, and a backward integration footprint covering 15 APIs (72% integration across inputs).

Supriya Lifescience Limited Business Segment

• Therapeutic segments and FY 2024–25 product performance (revenue stated as “H” in report; unit header indicates rupees crore):
  • Analgesic: Rs 52.24 crore; up 172.53% year‑on‑year, driven by scale‑up beyond top three molecules.

  • Anti‑histamine: Rs 72.54 crore; down 15.64% year‑on‑year amid portfolio rebalance and diversification across geographies.

  • Vitamins: Rs 73.57 crore; up 1.77% year‑on‑year with steady regulated market traction.

  • Anti‑asthmatic: Rs 44.87 crore; up 12.86% year‑on‑year on registrations and demand recovery.

  • Anti‑allergic: Rs 28.03 crore; down 8.04% year‑on‑year due to mix and pricing pressures.

• Geographic split (FY 2024–25; revenue from exports Rs 575.01 crore, 85% of total):
  • India — Rs 101.48 crore (15.0%).

  • International — Rs 575.01 crore (85.0%).

  • Europe within international — Rs 213.35 crore (37.1%), reflecting highest regional contribution with expanding CEP footprint.

  • Latin America within international — Rs 125.36 crore (21.8%), doubling share on new registrations and long‑term contracts.

  • Asia ex‑India within international — Rs 94.88 crore (16.5%), supported by diversified approvals.
    

Supriya Lifescience Limited Key Management

• Dr. Satish Waman Wagh — Chairman & Executive Director.

• Dr. Saloni Satish Wagh — Managing Director.

• Ms. Shivani Satish Wagh — Joint Managing Director.

• Mrs. Smita Satish Wagh — Whole Time Director.

• Mr. Balasaheb Gulabrao Sawant — Whole Time Director.

• Mr. Krishna Raghunathan — Chief Financial Officer.

• Ms. Prachi Sathe — Company Secretary & Compliance Officer.

Latest Updates on Supriya Lifescience Limited

• Commissioned state‑of‑the‑art Module E at Lote Parshuram, increasing installed capacity from 597 KLPD to 932 KLPD with enhanced automation.

• Signed a 10‑year exclusive API supply contract with a leading European company; expected peak annual revenue of Rs 60.00 crore from FY 2026–27.

• Commercialised major CDMO projects and identified two additional high‑potential CMO opportunities in APIs and advanced intermediates.

• Achieved exports of Rs 575.01 crore (85% of revenue); Europe 37.1%, LATAM 21.8%, Asia ex‑India 16.5%, with 70% of total revenue from >5‑year customer relationships.

• Expanded R&D/formulations capabilities at Ambernath, targeting value‑added injectables, tablets, capsules, and complex formulations; plan to add ~4 APIs and ~10 formulations annually.

• Renewed and expanded regulatory portfolio (CEPs and approvals) enabling deeper EU and regulated market penetration; reaffirmed ICRA long‑term rating A (Positive).

Leadership guidance: on track to target around Rs 1,000 crore revenue by FY 2026–27, supported by Ambernath ramp‑up and CDMO growth.